Savara Amends Loan Agreement, Securing Up to $75M Additional Financing Contingent on MOLBREEVI FDA Approval
SVRA has more than doubled off its 52-week low of $1.89.
Summary
Savara Inc. amended its loan agreement to secure up to $75 million in additional term loans, contingent on FDA approval of its MOLBREEVI product, and extended key financial covenant compliance dates.
Key Events · Financing and Capital Events · SVRA
-
Secures Additional Term Loans
The company amended its loan agreement to provide for up to an aggregate of $105 million in term loans, with $75 million of additional funds now available.
-
FDA Approval Contingency
The ability to draw the additional $75 million is contingent upon FDA approval of MOLBREEVI for the treatment of aPAP, directly linking financing to a major product milestone.
-
Extended Financial Covenants
Compliance dates for the unrestricted cash requirement and the minimum trailing six-month revenue covenant have been extended to April 1, 2027, and September 30, 2027, respectively.
-
Intellectual Property as Collateral
The amendment grants lenders a first-priority perfected security interest in the company's intellectual property.
Analysis · SVRA · Life Sciences
Savara Inc. has significantly bolstered its financial flexibility by amending its loan agreement with Hercules Capital, Inc., making up to an additional $75 million in term loans available. This capital is strategically tied to the anticipated FDA approval of its key product candidate, MOLBREEVI, for aPAP, following the positive Phase 3 results announced earlier this month. The amendment also extends compliance dates for critical financial covenants, providing the company with a longer runway and reduced near-term financial pressure. This move demonstrates lender confidence in MOLBREEVI's potential and provides crucial funding for potential commercialization or further development post-approval.
How filings like this one have moved
In the 30 days to Oct 3, 2026, 36.5% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.60%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SVRA was trading at $5.79 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $1.89 to $7.01. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.